PART I . We are a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of innovative, highly differentiated oral medicines that address significant health problems and meaningfully improve patients lives. We are committed to advancing novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologie...
Q2 FY2026 — expected 2026-09-06
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-02-26 | 2025-12-31 | 0001193125-26-073395 | EDGAR | 104K words |
| 2025-02-27 | 2024-12-31 | 0000950170-25-028355 | EDGAR | — |
| 2024-02-22 | 2023-12-31 | 0000950170-24-018414 | EDGAR | — |
| 2023-02-23 | 2022-12-31 | 0000950170-23-003935 | EDGAR | — |
| 2022-02-24 | 2021-12-31 | 0000950170-22-001860 | EDGAR | — |
| 2021-03-11 | 2020-12-31 | 0001564590-21-012240 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-05 | 2026-06-30 | 0001193125-26-333849 | EDGAR | — |
| 2025-11-04 | 2025-09-30 | 0001193125-25-263550 | EDGAR | 70K words |
| 2025-08-11 | 2025-06-30 | 0000950170-25-106229 | EDGAR | — |
| 2025-05-09 | 2025-03-31 | 0000950170-25-067498 | EDGAR | — |
| 2024-10-31 | 2024-09-30 | 0000950170-24-119249 | EDGAR | — |
| 2024-08-07 | 2024-06-30 | 0000950170-24-092275 | EDGAR | — |
| 2024-05-02 | 2024-03-31 | 0000950170-24-051567 | EDGAR | — |
| 2023-11-02 | 2023-09-30 | 0000950170-23-057743 | EDGAR | — |
| 2023-08-03 | 2023-06-30 | 0000950170-23-037581 | EDGAR | — |
| 2023-05-04 | 2023-03-31 | 0000950170-23-017462 | EDGAR | — |
| 2022-11-03 | 2022-09-30 | 0000950170-22-021543 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-015745 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-05 | 0001193125-26-333834 | EDGAR | — |
| 2026-07-27 | 0001193125-26-318078 | EDGAR | — |
| 2026-03-27 | 0001193125-26-129170 | EDGAR | 1K words |
| 2026-02-26 | 0001193125-26-073561 | EDGAR | — |
| 2026-02-26 | 0001193125-26-073386 | EDGAR | — |
| 2026-01-13 | 0001193125-26-011104 | EDGAR | — |
| 2025-12-10 | 0001193125-25-314422 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310670 | EDGAR | — |
| 2025-12-08 | 0001193125-25-310572 | EDGAR | — |
| 2025-11-04 | 0001193125-25-263540 | EDGAR | — |
114 total filings indexed. 86 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001815442 |
| Ticker | KYMR |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.kymeratx.com |
| Listed | 2020-08-21 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/KYMR (~200 tokens, structured JSON with cryptographic provenance)